

P20257.P08

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P20257Serial No.
09/674,526INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)Applicant
H. SUSAKI et al.Filing Date
November 21, 2000Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
JR	5 6 8 8 9 3 1	11/18/97	NOGUSA et al.	536	20	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
JR	6 - 8 7 7 4 6	03/29/94	JAPAN			
JR	1 1 - 9 2 4 0 5	04/06/99	JAPAN			
JR	9 2 / 1 4 7 5 9	09/03/92	W. I. P. O.			
JR	9 4 / 1 9 3 7 6	09/01/94	W. I. P. O.			
JR	9 7 / 4 6 2 6 0	12/11/97	W. I. P. O.			
JR	9 8 / 1 3 0 5 9	04/02/98	W. I. P. O.			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JR	1	English Language Abstract of JP 6-87746 (3-29-1994)
JR	2	English Language Abstract of JP 11-92405 (4-6-1999)
JR	3	Abstracts of 10th Meeting of the Japan Society of Drug Delivery System, pp. 279 (1994).
JR	4	Abstracts of 9th Annual Meeting of Japanese Society for the Study of Xenobiotics, pp. 292 (1994).
JR	5	Abstracts of 19th Seminar of Trends in Research and Development, pp. D-9 - D-12 (1995).
JR	6	Abstracts of 12th Colloid and Interface Technology Symposium, The Chemical Society of Japan, pp. 51-58 (1995).
JR	7	Gene M. Dubowchik et al., "Monomethoxytrityl (MMT) as a Versatile Amino Protecting Group for Complex Prodrugs of Anticancer Compounds Sensitive to Strong Acids, Bases and Nucleophiles", Tetrahedron Letters, Vol. 38, No. 30, pp. 5257-5260 (1997).
JR	8	Gene M. Dubowchik et al., "Efficient Mitomycin C Coupling With Stable p-Nitrophenyl-Benzyl Carbonates Using N-Hydroxybenzotriazole as a Catalytic Additive", Tetrahedron Letters, Vol. 38, No. 30, pp. 5261-5264 (1997).

EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

April 1, 2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2

20257.P08

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P20257Serial No.
09/674,526INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)Applicant
H. SUSAKI et al.Filing Date
November 21, 2000Group
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- 9 Gene M. Dubowchik et al., "Cathepsin B-Sensitive Dipeptide Prodrugs.1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin", Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 3341-3346 (1998).
- 10 Gene M. Dubowchik et al., "Cathepsin B-Sensitive Dipeptide Prodrugs.2. Models of Anticancer Drugs Paclitaxel (Taxol®), Mitomycin C and Doxorubicin", Bioorganic & Medicinal Chemistry Letters, Vol. 8, pp. 3347-3352 (1998).
- 11 Franciscus M.H. de Groot et al., "Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin", J. Med. Chem., Vol. 42, pp. 5277-5283 (1999).
- 12 Ion Niculescu-Duvaz et al., "Self-Immolative Anthracycline Prodrugs for Suicide Gene Therapy", J. Med. Chem., Vol. 42, pp. 2485-2489 (1999).
- 13 Dan Niculescu-Duvaz et al., "Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy", J. Med. Chem., Vol. 41, pp. 5297-5309 (1998).
- 14 Richard B. Greenwald et al., "Drug Delivery Systems Employing 1,4- or 1,6-Elimination: Poly(ethylene glycol) Prodrugs of Amine-Containing Compounds", J. Med. Chem., Vol. 42, pp. 3657-3667 (1999).
- 15 Yu-Ling Leu et al., "Design and Synthesis of Water-Soluble Glucuronide Derivatives of Camptothecin for Cancer Prodrug Monotherapy and Antibody-Directed Enzyme Prodrug Therapy (ADEPT)", J. Med. Chem., Vol. 42, pp. 2623-2628 (1999).
- 16 Ruben G.G. Leenders et al., "Novel Anthracycline-spacer- β -glucuronide, - β -glucoside, and - β -galactoside Prodrugs for Application in Selective Chemotherapy", Bioorganic & Medicinal Chemistry, Vol. 7, pp. 1597-1610 (1999).

EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

April 1, 2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]